PD-1 inhibitor with recombinant human hyaluronidase

This page covers all PD-1 inhibitor with recombinant human hyaluronidase drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1; hyaluronic acid (via berahyaluronidase alfa).

Targets

PD-1; hyaluronic acid (via berahyaluronidase alfa)

Phase 3 pipeline (1)

• Pembrolizumab Formulated with Berahyaluronidase Alfa · Merck Sharp & Dohme LLC · Oncology
  Pembrolizumab blocks PD-1 on immune cells to restore anti-tumor immunity, while berahyaluronidase alfa enhances subcutaneous drug delivery by temporarily degrading hyaluronic acid in tissue.

Patent intelligence

• pd 1 inhibitor with recombinant human hyaluronidase patent landscape — aggregated cliff calendar, attackable patents, originator estates